Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities
Authors
Cooksley, Timothy JGirotra, M.
Ginex, P.
Gordon, R. A.
Anderson, R.
Blidner, A.
Choi, J.
Dougan, M.
Glezerman, I.
Gupta, D.
Johnson, D.
Shannon, V. R.
Suarez-Almazor, M.
Rapoport, B. L.
Affiliation
The Christie and Manchester University Foundation Trust, Manchester, UK.Issue Date
2020
Metadata
Show full item recordAbstract
Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment, transforming outcomes in melanoma and showing benefit in a range of malignancies. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Immune-mediated endocrinopathies include hypophysitis, thyroiditis, and insulin-dependent diabetes mellitus. These presentations, which may be vague and non-specific, can be life-threatening if not diagnosed and treated appropriately. This review considers the work-up and management of immune-mediated endocrinopathies and also considers the role of advanced practice practitioners in the management of immune-mediated toxicities. These state-of-the-art MASCC recommendations represent a comprehensive overview of the management and clinical work-up in those in whom the diagnosis should be considered.Citation
Cooksley T, Girotra M, Ginex P, Gordon RA, Anderson R, Blidner A, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020.Journal
Supportive Care in CancerDOI
10.1007/s00520-020-05709-1PubMed ID
32856213Additional Links
https://dx.doi.org/10.1007/s00520-020-05709-1Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s00520-020-05709-1
Scopus Count
Collections
Related articles
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.
- Authors: Suarez-Almazor ME, Pundole X, Abdel-Wahab N, Johnson DB, Gupta D, Glezerman I, Cooksley T, Anderson R, Blidner A, Choi J, Dougan M, Ginex P, Girotra M, Shannon VR, Rapoport BL
- Issue date: 2020 Dec
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
- Authors: Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL
- Issue date: 2020 Dec
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
- Authors: Shannon VR, Anderson R, Blidner A, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson DB, Suarez-Almazor ME, Rapoport BL
- Issue date: 2020 Dec
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.
- Authors: Choi J, Anderson R, Blidner A, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL, Lacouture ME
- Issue date: 2020 Dec
- Cancer immunotherapy-related adverse events: causes and challenges.
- Authors: Blidner AG, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL, Anderson R
- Issue date: 2020 Dec